AMGN NASDAQ
Amgen Inc.
1W: +2.0%
1M: +7.1%
3M: +16.2%
YTD: +39.5%
1Y: +57.8%
3Y: +75.8%
5Y: +153.1%
$447.95
+3.32 (+0.75%)
After Hours: $449.16 (+1.21, +0.27%)
Weekly Expected Move ±4.0%
$404
$421
$439
$457
$475
Credit Risk of going bust: lower than 74% of companies Debt: 19.2% of company value Bonds: $1.31B held by 639 funds, 79 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $7.22 (down 98%), Amgen Inc. would be worth roughly what it owes.
Total debt $57.30B against a stock market value of $240.38B.
Distance to default 8.24 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $31.37B (short-term plus half of long-term), stock volatility 29.5%; Altman Z 2.36. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $7.22 (down 98%), Amgen Inc. would be worth roughly what it owes.
Total debt $57.30B against a stock market value of $240.38B.
Distance to default 8.24 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $31.37B (short-term plus half of long-term), stock volatility 29.5%; Altman Z 2.36. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
29 relationships23
As Filer
counterparties named
6
As Counterparty
mentioned by others
5
Rel. Types
2021-06-01
Earliest Filing
2025-08-25
Latest Filing
partner: 12
target: 6
acquirer: 2
supplier: 2
investor: 1
Counterparties (Filed by AMGN)
23 relationshipsCompanies named in AMGN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Horizon Therapeutics plc | HZNP | target | Target company acquired by Amgen Inc. in a cash and stock transaction. | 2023-10-06 | View |
| Pillartree Limited | — | acquirer | Wholly owned subsidiary of Amgen Inc. that acquired Horizon Therapeutics plc. | 2023-10-06 | View |
| Horizon Therapeutics plc | HZNP | target | Target of Amgen's acquisition funded by the senior notes offering. | 2023-03-02 | View |
| BeiGene, Ltd. | BGNE | investor | Amgen amended Share Purchase Agreement to relinquish director appointment right and change accounting method for equity | 2023-01-31 | View |
| Horizon Therapeutics plc | HZNP | target | Proposed acquisition target subject to FTC review and HSR Act waiting period. | 2023-01-31 | View |
| Pillartree Limited | — | partner | Party to the Transaction Agreement alongside Amgen and Horizon Therapeutics. | 2023-01-31 | View |
| Five Prime Therapeutics, Inc. | — | supplier | Acquired IPR&D assets by Amgen in 2021, impacting non-GAAP financial measures. | 2023-01-31 | View |
| Kyowa Kirin Co., Ltd. | — | supplier | Received licensing-related upfront payment from Amgen in 2021. | 2023-01-31 | View |
| Horizon Therapeutics plc | — | target | Target company in the acquisition financed by the Term Loan Credit Facility | 2022-12-22 | View |
| Horizon Therapeutics plc | HZNP | target | Target company in acquisition by Pillartree Limited (wholly owned by Amgen) for $116.50 per share. | 2022-12-12 | View |
| Pillartree Limited | — | acquirer | Newly formed private limited company wholly owned by Amgen, acting as the acquirer of Horizon Therapeutics plc. | 2022-12-12 | View |
| Latham & Watkins LLP | SWIM | partner | Legal counsel providing opinion | 2022-08-18 | View |
| Novartis AG | NVSEF | partner | Amgen and Novartis modified terms of their collaboration agreement regarding Aimovig commercialization rights and royalt | 2022-01-31 | View |
| Citigroup Global Markets Inc. | — | partner | Underwriter for the sale of Senior Notes | 2021-08-09 | View |
| Morgan Stanley & Co. LLC | MS-PL | partner | Underwriter for the sale of Senior Notes | 2021-08-09 | View |
| Barclays Capital Inc. | BCLYF | partner | Underwriter for the sale of Senior Notes | 2021-08-09 | View |
| Goldman Sachs & Co. LLC | GSCE | partner | Underwriter for the sale of Senior Notes | 2021-08-09 | View |
| The Bank of New York Mellon Trust Company, N.A. | — | partner | Trustee for the Senior Notes indenture | 2021-08-09 | View |
| Teneobio, Inc. | — | target | Target of merger agreement with Amgen Inc. | 2021-07-27 | View |
| Tuxedo Merger Sub, Inc. | — | partner | Wholly owned subsidiary of Amgen used as merger vehicle. | 2021-07-27 | View |
| Fortis Advisors LLC | — | partner | Stockholder Representative in the Merger Agreement. | 2021-07-27 | View |
| AbbVie Inc. | ABBV | partner | Acquired TeneoOne, Inc., an affiliate of Teneobio. | 2021-07-27 | View |
| Kyowa Kirin Co., Ltd. | — | partner | License and Collaboration Agreement for development and commercialization of KHK4083 | 2021-06-01 | View |
Mentioned As Counterparty
6 mentionsOther companies that named AMGN in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| BEIGF BeOne Medicines Ltd. | partner | Original licensor under the Collaboration Agreement paying royalties to the Seller | 2025-08-25 | View |
| PODD INSULET CORP | supplier | Insulet Corporation entered into Amendment 21 to the Supply Agreement and a Patent Assignment and License Agreement with | 2023-06-07 | View |
| TCRX TScan Therapeutics, Inc. | partner | Collaboration Agreement for target discovery in Crohn's disease with upfront payment and milestone payments. | 2023-05-09 | View |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | partner | Original licensee of Olpasiran under a 2016 collaboration and license agreement | 2022-11-10 | View |
| IDYA IDEAYA Biosciences, Inc. | partner | Clinical Trial Collaboration and Supply Agreement for IDE397/AMG 193 Combination Study | 2022-07-27 | View |
| JSPRW Amplitude Healthcare Acquisition Corp | investor | PIPE Investor subscribing for Class A Common Stock of AMHC. | 2021-09-29 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-27 | Officer/Director Change | View | |
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-07-31 | Other Events | View | |
| 2026-05-20 | Shareholder Vote | View | |
| 2026-05-19 | Officer/Director Change | View | |
| 2026-04-30 | Earnings Release; Exhibits | View | |
| 2026-04-22 | Officer/Director Change; Exhibits | View | |
| 2026-02-19 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-02-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-30 | Termination of Material Definitive Agreement; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-27 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-05-02 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-02-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2023-12-14 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR